Global Guideline for Type 2 Diabetes

Autores
Aschner, Pablo; Beck Nielsen, Henning; Bennet, Peter; Boulton, Andrew; Colagiuri, Ruth; Colagiuri, Stephen; Franz, Marion; Gadsby, Roger; Gagliardino, Juan Jose; Home, Philip; McGill, Marg; Manley, Susan; Marshall, Sally; Mbanya, Jean Claude; Neil, Andrew; Ramachandran, Ambady; Ramaiya, Kaushik; Roglic, Gojka; Schaper, Nicolaas; Siminerio, Linda; Sinclair, Alan; Snoek, Frank; Van Crombrugge, Paul; Vespasiani, Giacomo; Viswanathan, Vijay
Año de publicación
2014
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
There is now extensive evidence on the optimal management of diabetes, offering the opportunity of improving the immediate and long-term quality of life of those with diabetes. Unfortunately such optimal management is not reaching many, perhaps the majority, of the people who could benefi t. Reasons include the size and complexity of the evidencebase, and the complexity of diabetes care itself. One result is a lack of proven cost-effective resources for diabetes care. Another result is diversity of standards of clinical practice. Guidelines are one part of a process which seeks to address those problems. Many guidelines have appeared internationally, nationally, and more locally in recent years, but most of these have not used the rigorous new guideline methodologies for identifi cation and analysis of the evidence. Many countries around the world do not have the resources, either in expertise or fi nancially, that are needed to develop diabetes guidelines. Also such a repetitive approach would be enormously ineffi cient and costly. Published national guidelines come from relatively resource-rich countries, and may be of limited practical use in less well resourced countries. In 2005 the fi rst IDF Global Guideline for type 2 diabetes was developed. This presented a unique challenge as we tried to develop a guideline that is sensitive to resource and costeffectiveness issues. Many national guidelines address one group of people with diabetes in the context of one healthcare system, with one level of national and health-care resources. This is not true in the global context where, although every health-care system seems to be short of resources, the funding and expertise available for health-care vary widely between countries and even between localities. Despite the challenges, we feel that we found an approach which is at least partially successful in addressing this issue which we termed ‘Levels of care’ (see next page). This guideline represents an update of the fi rst guideline and extends the evidence base by including new studies and treatments which have emerged since the original guideline was produced in 2005. Funding is essential to an activity of this kind. IDF is grateful to a diversity of commercial partners for provision of unrestricted educational grants.
Fil: Aschner, Pablo. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Beck Nielsen, Henning. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Bennet, Peter. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Boulton, Andrew. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Colagiuri, Ruth. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Colagiuri, Stephen. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Franz, Marion. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Gadsby, Roger. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Gagliardino, Juan Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Cientifico Tecnológico La Plata. Centro de Endocrinologia Experimental y Aplicada (i); Argentina. Universidad Nacional de La Plata; Argentina. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Home, Philip. International Diabetes Federation Guideline Development Group; Bélgica
Fil: McGill, Marg. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Manley, Susan. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Marshall, Sally. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Mbanya, Jean Claude. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Neil, Andrew. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Ramachandran, Ambady. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Ramaiya, Kaushik. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Roglic, Gojka. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Schaper, Nicolaas. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Siminerio, Linda. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Sinclair, Alan. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Snoek, Frank. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Van Crombrugge, Paul. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Vespasiani, Giacomo. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Viswanathan, Vijay . International Diabetes Federation Guideline Development Group; Bélgica
Materia
Diabetes
Guidelines
Quality of Care
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/10505

id CONICETDig_da56cfd13845807a844c28760093666e
oai_identifier_str oai:ri.conicet.gov.ar:11336/10505
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Global Guideline for Type 2 DiabetesAschner, PabloBeck Nielsen, HenningBennet, PeterBoulton, AndrewColagiuri, RuthColagiuri, StephenFranz, MarionGadsby, RogerGagliardino, Juan JoseHome, PhilipMcGill, MargManley, SusanMarshall, SallyMbanya, Jean ClaudeNeil, Andrew Ramachandran, AmbadyRamaiya, KaushikRoglic, GojkaSchaper, NicolaasSiminerio, LindaSinclair, AlanSnoek, FrankVan Crombrugge, Paul Vespasiani, GiacomoViswanathan, Vijay DiabetesGuidelinesQuality of Carehttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3There is now extensive evidence on the optimal management of diabetes, offering the opportunity of improving the immediate and long-term quality of life of those with diabetes. Unfortunately such optimal management is not reaching many, perhaps the majority, of the people who could benefi t. Reasons include the size and complexity of the evidencebase, and the complexity of diabetes care itself. One result is a lack of proven cost-effective resources for diabetes care. Another result is diversity of standards of clinical practice. Guidelines are one part of a process which seeks to address those problems. Many guidelines have appeared internationally, nationally, and more locally in recent years, but most of these have not used the rigorous new guideline methodologies for identifi cation and analysis of the evidence. Many countries around the world do not have the resources, either in expertise or fi nancially, that are needed to develop diabetes guidelines. Also such a repetitive approach would be enormously ineffi cient and costly. Published national guidelines come from relatively resource-rich countries, and may be of limited practical use in less well resourced countries. In 2005 the fi rst IDF Global Guideline for type 2 diabetes was developed. This presented a unique challenge as we tried to develop a guideline that is sensitive to resource and costeffectiveness issues. Many national guidelines address one group of people with diabetes in the context of one healthcare system, with one level of national and health-care resources. This is not true in the global context where, although every health-care system seems to be short of resources, the funding and expertise available for health-care vary widely between countries and even between localities. Despite the challenges, we feel that we found an approach which is at least partially successful in addressing this issue which we termed ‘Levels of care’ (see next page). This guideline represents an update of the fi rst guideline and extends the evidence base by including new studies and treatments which have emerged since the original guideline was produced in 2005. Funding is essential to an activity of this kind. IDF is grateful to a diversity of commercial partners for provision of unrestricted educational grants.Fil: Aschner, Pablo. International Diabetes Federation Guideline Development Group; BélgicaFil: Beck Nielsen, Henning. International Diabetes Federation Guideline Development Group; BélgicaFil: Bennet, Peter. International Diabetes Federation Guideline Development Group; BélgicaFil: Boulton, Andrew. International Diabetes Federation Guideline Development Group; BélgicaFil: Colagiuri, Ruth. International Diabetes Federation Guideline Development Group; BélgicaFil: Colagiuri, Stephen. International Diabetes Federation Guideline Development Group; BélgicaFil: Franz, Marion. International Diabetes Federation Guideline Development Group; BélgicaFil: Gadsby, Roger. International Diabetes Federation Guideline Development Group; BélgicaFil: Gagliardino, Juan Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Cientifico Tecnológico La Plata. Centro de Endocrinologia Experimental y Aplicada (i); Argentina. Universidad Nacional de La Plata; Argentina. International Diabetes Federation Guideline Development Group; BélgicaFil: Home, Philip. International Diabetes Federation Guideline Development Group; BélgicaFil: McGill, Marg. International Diabetes Federation Guideline Development Group; BélgicaFil: Manley, Susan. International Diabetes Federation Guideline Development Group; BélgicaFil: Marshall, Sally. International Diabetes Federation Guideline Development Group; BélgicaFil: Mbanya, Jean Claude. International Diabetes Federation Guideline Development Group; BélgicaFil: Neil, Andrew. International Diabetes Federation Guideline Development Group; BélgicaFil: Ramachandran, Ambady. International Diabetes Federation Guideline Development Group; BélgicaFil: Ramaiya, Kaushik. International Diabetes Federation Guideline Development Group; BélgicaFil: Roglic, Gojka. International Diabetes Federation Guideline Development Group; BélgicaFil: Schaper, Nicolaas. International Diabetes Federation Guideline Development Group; BélgicaFil: Siminerio, Linda. International Diabetes Federation Guideline Development Group; BélgicaFil: Sinclair, Alan. International Diabetes Federation Guideline Development Group; BélgicaFil: Snoek, Frank. International Diabetes Federation Guideline Development Group; BélgicaFil: Van Crombrugge, Paul. International Diabetes Federation Guideline Development Group; BélgicaFil: Vespasiani, Giacomo. International Diabetes Federation Guideline Development Group; BélgicaFil: Viswanathan, Vijay . International Diabetes Federation Guideline Development Group; BélgicaElsevier Ireland2014-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/10505Aschner, Pablo; Beck Nielsen, Henning; Bennet, Peter; Boulton, Andrew; Colagiuri, Ruth; et al.; Global Guideline for Type 2 Diabetes; Elsevier Ireland; Diabetes Research And Clinical Practice; 104; 1; 4-2014; 1-520168-8227enginfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.diabres.2012.10.001info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:49:31Zoai:ri.conicet.gov.ar:11336/10505instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:49:32.133CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Global Guideline for Type 2 Diabetes
title Global Guideline for Type 2 Diabetes
spellingShingle Global Guideline for Type 2 Diabetes
Aschner, Pablo
Diabetes
Guidelines
Quality of Care
title_short Global Guideline for Type 2 Diabetes
title_full Global Guideline for Type 2 Diabetes
title_fullStr Global Guideline for Type 2 Diabetes
title_full_unstemmed Global Guideline for Type 2 Diabetes
title_sort Global Guideline for Type 2 Diabetes
dc.creator.none.fl_str_mv Aschner, Pablo
Beck Nielsen, Henning
Bennet, Peter
Boulton, Andrew
Colagiuri, Ruth
Colagiuri, Stephen
Franz, Marion
Gadsby, Roger
Gagliardino, Juan Jose
Home, Philip
McGill, Marg
Manley, Susan
Marshall, Sally
Mbanya, Jean Claude
Neil, Andrew
Ramachandran, Ambady
Ramaiya, Kaushik
Roglic, Gojka
Schaper, Nicolaas
Siminerio, Linda
Sinclair, Alan
Snoek, Frank
Van Crombrugge, Paul
Vespasiani, Giacomo
Viswanathan, Vijay
author Aschner, Pablo
author_facet Aschner, Pablo
Beck Nielsen, Henning
Bennet, Peter
Boulton, Andrew
Colagiuri, Ruth
Colagiuri, Stephen
Franz, Marion
Gadsby, Roger
Gagliardino, Juan Jose
Home, Philip
McGill, Marg
Manley, Susan
Marshall, Sally
Mbanya, Jean Claude
Neil, Andrew
Ramachandran, Ambady
Ramaiya, Kaushik
Roglic, Gojka
Schaper, Nicolaas
Siminerio, Linda
Sinclair, Alan
Snoek, Frank
Van Crombrugge, Paul
Vespasiani, Giacomo
Viswanathan, Vijay
author_role author
author2 Beck Nielsen, Henning
Bennet, Peter
Boulton, Andrew
Colagiuri, Ruth
Colagiuri, Stephen
Franz, Marion
Gadsby, Roger
Gagliardino, Juan Jose
Home, Philip
McGill, Marg
Manley, Susan
Marshall, Sally
Mbanya, Jean Claude
Neil, Andrew
Ramachandran, Ambady
Ramaiya, Kaushik
Roglic, Gojka
Schaper, Nicolaas
Siminerio, Linda
Sinclair, Alan
Snoek, Frank
Van Crombrugge, Paul
Vespasiani, Giacomo
Viswanathan, Vijay
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Diabetes
Guidelines
Quality of Care
topic Diabetes
Guidelines
Quality of Care
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv There is now extensive evidence on the optimal management of diabetes, offering the opportunity of improving the immediate and long-term quality of life of those with diabetes. Unfortunately such optimal management is not reaching many, perhaps the majority, of the people who could benefi t. Reasons include the size and complexity of the evidencebase, and the complexity of diabetes care itself. One result is a lack of proven cost-effective resources for diabetes care. Another result is diversity of standards of clinical practice. Guidelines are one part of a process which seeks to address those problems. Many guidelines have appeared internationally, nationally, and more locally in recent years, but most of these have not used the rigorous new guideline methodologies for identifi cation and analysis of the evidence. Many countries around the world do not have the resources, either in expertise or fi nancially, that are needed to develop diabetes guidelines. Also such a repetitive approach would be enormously ineffi cient and costly. Published national guidelines come from relatively resource-rich countries, and may be of limited practical use in less well resourced countries. In 2005 the fi rst IDF Global Guideline for type 2 diabetes was developed. This presented a unique challenge as we tried to develop a guideline that is sensitive to resource and costeffectiveness issues. Many national guidelines address one group of people with diabetes in the context of one healthcare system, with one level of national and health-care resources. This is not true in the global context where, although every health-care system seems to be short of resources, the funding and expertise available for health-care vary widely between countries and even between localities. Despite the challenges, we feel that we found an approach which is at least partially successful in addressing this issue which we termed ‘Levels of care’ (see next page). This guideline represents an update of the fi rst guideline and extends the evidence base by including new studies and treatments which have emerged since the original guideline was produced in 2005. Funding is essential to an activity of this kind. IDF is grateful to a diversity of commercial partners for provision of unrestricted educational grants.
Fil: Aschner, Pablo. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Beck Nielsen, Henning. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Bennet, Peter. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Boulton, Andrew. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Colagiuri, Ruth. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Colagiuri, Stephen. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Franz, Marion. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Gadsby, Roger. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Gagliardino, Juan Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Cientifico Tecnológico La Plata. Centro de Endocrinologia Experimental y Aplicada (i); Argentina. Universidad Nacional de La Plata; Argentina. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Home, Philip. International Diabetes Federation Guideline Development Group; Bélgica
Fil: McGill, Marg. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Manley, Susan. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Marshall, Sally. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Mbanya, Jean Claude. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Neil, Andrew. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Ramachandran, Ambady. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Ramaiya, Kaushik. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Roglic, Gojka. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Schaper, Nicolaas. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Siminerio, Linda. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Sinclair, Alan. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Snoek, Frank. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Van Crombrugge, Paul. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Vespasiani, Giacomo. International Diabetes Federation Guideline Development Group; Bélgica
Fil: Viswanathan, Vijay . International Diabetes Federation Guideline Development Group; Bélgica
description There is now extensive evidence on the optimal management of diabetes, offering the opportunity of improving the immediate and long-term quality of life of those with diabetes. Unfortunately such optimal management is not reaching many, perhaps the majority, of the people who could benefi t. Reasons include the size and complexity of the evidencebase, and the complexity of diabetes care itself. One result is a lack of proven cost-effective resources for diabetes care. Another result is diversity of standards of clinical practice. Guidelines are one part of a process which seeks to address those problems. Many guidelines have appeared internationally, nationally, and more locally in recent years, but most of these have not used the rigorous new guideline methodologies for identifi cation and analysis of the evidence. Many countries around the world do not have the resources, either in expertise or fi nancially, that are needed to develop diabetes guidelines. Also such a repetitive approach would be enormously ineffi cient and costly. Published national guidelines come from relatively resource-rich countries, and may be of limited practical use in less well resourced countries. In 2005 the fi rst IDF Global Guideline for type 2 diabetes was developed. This presented a unique challenge as we tried to develop a guideline that is sensitive to resource and costeffectiveness issues. Many national guidelines address one group of people with diabetes in the context of one healthcare system, with one level of national and health-care resources. This is not true in the global context where, although every health-care system seems to be short of resources, the funding and expertise available for health-care vary widely between countries and even between localities. Despite the challenges, we feel that we found an approach which is at least partially successful in addressing this issue which we termed ‘Levels of care’ (see next page). This guideline represents an update of the fi rst guideline and extends the evidence base by including new studies and treatments which have emerged since the original guideline was produced in 2005. Funding is essential to an activity of this kind. IDF is grateful to a diversity of commercial partners for provision of unrestricted educational grants.
publishDate 2014
dc.date.none.fl_str_mv 2014-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/10505
Aschner, Pablo; Beck Nielsen, Henning; Bennet, Peter; Boulton, Andrew; Colagiuri, Ruth; et al.; Global Guideline for Type 2 Diabetes; Elsevier Ireland; Diabetes Research And Clinical Practice; 104; 1; 4-2014; 1-52
0168-8227
url http://hdl.handle.net/11336/10505
identifier_str_mv Aschner, Pablo; Beck Nielsen, Henning; Bennet, Peter; Boulton, Andrew; Colagiuri, Ruth; et al.; Global Guideline for Type 2 Diabetes; Elsevier Ireland; Diabetes Research And Clinical Practice; 104; 1; 4-2014; 1-52
0168-8227
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1016/j.diabres.2012.10.001
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier Ireland
publisher.none.fl_str_mv Elsevier Ireland
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842268978486968320
score 13.13397